Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL CYPIONATE.
DIETHYLSTILBESTROL vs ESTRADIOL CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
1-5 mg intramuscularly every 3-4 weeks.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Category C
Category D/X
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."